Study Shows Nivolumab Survival Benefit in Head and Neck Cancer

Share this content:
Bristol-Myers Squibb has announced the early closure of its CheckMate-141 trial because it has already met its primary endpoint.
Bristol-Myers Squibb has announced the early closure of its CheckMate-141 trial because it has already met its primary endpoint.

Bristol-Myers Squibb has announced the early closure of its CheckMate-141 trial because it has already met its primary endpoint, per an assessment conducted by an independent Data Monitoring Committee.

The pivotal phase 3 trial demonstrated superior overall survival with nivolumab (Opdivo) compared with investigator's choice of treatment in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).1

“With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options,” said Michael Giordano, MD, senior vice president, head of Oncology Development, Bristol-Myers Squibb.

CheckMate-141 is an open-label study that evaluated nivolumab compared with investigator's choice of therapy. A total of 361 participants with SCCHN who experienced disease progression on or within 6 months of platinum therapy were randomly assigned 2:1 to receive nivolumab 3 mg/kg intravenously every 2 weeks, or cetuximab, methotrexate, or docetaxel until disease progression or unacceptable toxicity.

The primary endpoint is overall survival with objective response rate and progression-free survival as secondary endpoints.

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody already approved by the U.S. Food and Drug Administration for the treatment of BRAF V600 wild-type or mutation-positive unresectable or metastatic melanoma as monotherapy, unresectable or metastatic melanoma in combination with ipilimumab, metastatic non-small cell lung cancer after progression on or after platinum-based chemotherapy, and advanced renal cell carcinoma after prior antiangiogenic therapy.

RELATED: HPV-16 in Oral Cavity Associated With Increased Risk of Oropharyngeal Squamous Cell Carcinoma

In terms of safety, rash, musculoskeletal pain, constipation, diarrhea, and decreased appetite are frequently reported with single-agent nivolumab treatment.

Reference

  1. CheckMate -141, a pivotal phase 3 Opdivo (nivolumab) head and neck cancer trial, stopped early [news release]. Princeton, NJ: Bristol-Myers Squibb; January 28, 2016. http://news.bms.com/press-release/checkmate-141-pivotal-phase-3-opdivo-nivolumab-head-and-neck-cancer-trial-stopped-earl. Accessed January 29, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs